跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AURO-RIVASTIGMINE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AURO-RIVASTIGMINE
Authorized
STANDARD
AURO-RIVASTIGMINE
auro pharma inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
02bfb880f86cf423
Company
auro pharma inc
Type
Standard
Approval Details
Approval Id
02bfb880f86cf423
Drug Approval Canada Name
AURO-RIVASTIGMINE
Product Name
AURO-RIVASTIGMINE
Status
Dormant
Status Date
2018-08-01
Original Market Date
2016-04-12
Din
02427575
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
12:04.00
Atc Original
N06DA03 RIVASTIGMINE
Atc Name
n 06 da 03
Aig Number
0140521002
Company Name
auro pharma inc
Company Address
3700 Steeles Avenue West, Suite 402, Woodbridge, Ontario, Canada, L4L 8K8
Active Ingredients
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)
3 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
02bfb880f86cf423
Type
Standard
Back to Health Canada Approvals